TP53 and colorectal carcinoma: Furthermore, a novel RING-type E3 ubiquitin-linked enzyme, RNF126, promoted CRC progression and induced FOLFOX treatment resistance by enhancing p53 ubiquitination and degradation (Wang et al. 2020a, b).